SNGX Soligenix Inc.

2.27
+0.07  (3%)
Previous Close 2.20
Open 2.20
Price To book 3.60
Market Cap 12991528
Shares 5,723,140
Volume 33,566
Short Ratio 7.97
Av. Daily Volume 208,243

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial complete.
SGX201
Radiation Enteritis
Phase 3 data due 1H 2018.
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3 initiation announced July 27, 2017.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer
Phase 3 planned for 2018.
SGX203
Pediatric Crohn’s Disease

Latest News

  1. Soligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III Trials
  2. Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
  3. Soligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
  4. Soligenix Announces $1.5 Million NCI SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
  5. Dusquetide as a Potential Solution to Antimicrobial Resistant Bacteria to be Presented at the 2017 World Anti-Microbial Resistance Congress
  6. Soligenix to Present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City
  7. Soligenix to Present at the 8th Annual Investing for Cures Forum in New York City
  8. Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell
  9. Featured Company News - Soligenix Receives $2.5 million in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
  10. Soligenix Receives $2.5M in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
  11. Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results
  12. Soligenix (SNGX): What Can We Expect from the Ongoing Phase III Study of SGX942 based on the Phase II Results?
  13. Soligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing
  14. Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
  15. Today's Research Reports on Stocks to Watch: Soligenix and Aurinia Pharmaceuticals
  16. Dusquetide Technology Platform to be Presented at the 2017 Drug Discovery and Therapy World Congress
  17. Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
  18. Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
  19. Soligenix, Inc. :SNGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
  20. What Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None